Tamoxifen for advanced pancreatic SPTP
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests whether tamoxifen, a hormone therapy drug, can shrink or slow down advanced solid pseudopapillary tumors of the pancreas (SPTP) that have estrogen and progesterone receptors. It may be an option for people whose tumors cannot be removed by surgery or have come back after other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 14 to 80 years old.
- You have a rare type of pancreatic tumor called solid pseudopapillary tumor (SPTP) that tests positive for estrogen and progesterone receptors (ER/PR+).
- Your tumor is advanced (cannot be removed by surgery) or has spread to other parts of your body, or it has come back after prior treatment.
- You have at least one tumor that can be seen and measured on a scan.
- You are able to walk and take care of yourself (or are in bed less than half the day).
- You do not have serious health problems like severe heart, kidney, liver, or lung disease, or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine that targets cancer cells with specific proteins, to see if it can stop the growth of advanced pancreatic and breast cancer when other treatments have stopped working. It is an umbrella study, which means different protein-matched drugs are tested for different cancer types.
This early-stage trial tests a new drug called ES502 for patients with advanced cancers (including pancreatic cancer) that have a specific genetic mutation and certain immune markers. The study aims to find the right dose and see if it helps shrink tumors.
This trial tests whether tamoxifen, a hormone-blocking pill, can prevent pancreatic cysts from turning into cancer in people who are not having surgery to remove the cyst right away.
This trial tests a new treatment, PTM-101, placed during a laparoscopy procedure for people with pancreatic cancer that can be removed with surgery. It aims to see if adding this treatment before standard chemotherapy helps improve outcomes.
This trial tests a new medicine (TTI-101) combined with targeted radiation for people with pancreatic cancer that is either borderline or locally advanced. The goal is to see if this combination can shrink or control the cancer better than usual treatments.
This study tests a new targeted drug called sotorasib combined with standard chemotherapy for people with advanced pancreatic cancer that has a specific KRAS G12C mutation. The goal is to see if the combination works better than chemotherapy alone.
Hear when a new Pancreatic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.